AI Article Synopsis
- Olanzapine, a second-generation antipsychotic, may lead to metabolic issues and a higher risk of developing type 2 diabetes, especially affecting the hypothalamus, which regulates metabolism.
- The study aimed to investigate the acute effects of olanzapine on gene expression and kinase activity in the hypothalamus of rats under controlled insulin and glucose levels.
- Results showed that olanzapine activated inflammatory pathways while reducing the body's ability to manage stress and G protein-coupled receptor functions, highlighting potential areas for reducing diabetes risk in patients on antipsychotic medication.
Article Abstract
Olanzapine is a second-generation antipsychotic that disrupts metabolism and is associated with an increased risk of type 2 diabetes. The hypothalamus is a key region in the control of whole-body metabolic homeostasis. The objective of the current study was to determine how acute peripheral olanzapine administration affects transcription and serine/threonine kinase activity in the hypothalamus. Hypothalamus samples from rats were collected following the pancreatic euglycemic clamp, thereby allowing us to study endpoints under steady state conditions for plasma glucose and insulin. Olanzapine stimulated pathways associated with inflammation, but diminished pathways associated with the capacity to combat endoplasmic reticulum stress and G protein-coupled receptor activity. These pathways represent potential targets to reduce the incidence of type 2 diabetes in patients taking antipsychotics.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10947847 | PMC |
| http://dx.doi.org/10.1016/j.psyneuen.2024.106987 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!